Birchler Brian

Birchler Brian, EVP of Corporate and Development Operations, has demonstrated a clear selling bias in his trading activity involving Ionis Pharmaceuticals (IONS), the sole company represented in his SEC Form 4 filings. Over 30 reported transactions, his total sell value of $4.48 million significantly outweighs his total buy value of $1.88 million. The recent activity reinforces this trend, with eight sales since October 2025 and no purchases in the same period. Notably, his largest disposals occurred in early 2026, including a $513,047 sale on January 30 and a $636,932 transaction on January 16, following smaller but consistent sales in late 2025—such as $609,379 on November 6 and $897,398 on October 15. The pattern suggests a methodical reduction in holdings, often preceded by awards or derivative transactions (coded "A" or "M") that show no immediate dollar value. For example, multiple zero-value awards on January 15, 2026, preceded the January 16 and January 30 sales. Smaller transactions, like the $17,152 sale on February 27, 2026, and earlier sales in 2024—such as $226,725 on January 17—indicate periodic divestments rather than a single liquidation. While the sales are substantial, they appear structured, with no evidence of abrupt or irregular timing. The absence of recent buys, coupled with the consistency of disposals, points to a deliberate strategy of decreasing exposure to IONS over time.